NCT02452008 2025-12-19
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT01682187 2024-11-07
A Dose-Escalation Study in Participants With Recurrent Malignant Glioma
Eli Lilly and Company
Phase 1 Completed
NCT03206177 2024-08-07
Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
University of Oklahoma
Phase 1 Completed
NCT04605562 2021-09-05
Umbrella Biomarker-Guided Therapy in NPC
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT01246986 2021-01-12
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Eli Lilly and Company
Phase 2 Completed
NCT02240433 2020-02-05
A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)
Eli Lilly and Company
Phase 1 Completed
NCT03470350 2019-07-24
EORTC1615
The Netherlands Cancer Institute
Phase 1/2 Withdrawn
NCT01373164 2018-05-16
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT01220271 2017-02-16
A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma
Eli Lilly and Company
Phase 1/2 Completed
NCT02304419 2016-10-05
A Study of Galunisertib on the Immune System in Participants With Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02154646 2016-02-10
A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body
Eli Lilly and Company
Phase 1 Completed
NCT01722825 2014-07-01
Study of LY2157299 in Japanese Participants With Cancer
Eli Lilly and Company
Phase 1 Completed